Grald Simonneau

List of Publications by Year in Descending Order

331 papers	64,177 citations	110 h-index	252 g-index
350 ext. papers	75,872 ext. citations	10.2 avg, IF	7.2 L-index

#	Paper	IF	Citations
331	Chronic thromboembolic pulmonary hypertension: the magic of pathophysiology.. *Annals of Cardiothoracic Surgery*, **2022**, 11, 106-119	4.7	3
330	Pulmonary thromboendarterectomy: The Marie Lannelongue Hospital experience.. *Annals of Cardiothoracic Surgery*, **2022**, 11, 143-150	4.7	1
329	ERS statement on chronic thromboembolic pulmonary hypertension. *European Respiratory Journal*, **2021**, 57,	13.6	70
328	Screening for pulmonary arterial hypertension in adults carrying a mutation. *European Respiratory Journal*, **2021**, 58,	13.6	11
327	External validation of a refined 4-strata risk assessment score from the French pulmonary hypertension Registry. *European Respiratory Journal*, **2021**,	13.6	4
326	Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial. *Lancet Respiratory Medicine,the*, **2021**, 9, 573-584	35.1	22
325	Association between Initial Treatment Strategy and Long-Term Survival in Pulmonary Arterial Hypertension. *American Journal of Respiratory and Critical Care Medicine*, **2021**, 204, 842-854	10.2	13
324	Current strategies for managing chronic thromboembolic pulmonary hypertension: results of the worldwide prospective CTEPH Registry. *ERJ Open Research*, **2021**, 7,	3.5	9
323	Chronic thromboembolic pulmonary hypertension and totally implantable central venous access systems. *European Respiratory Journal*, **2021**, 57,	13.6	3
322	Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry. *Respiratory Medicine*, **2021**, 178, 106220	4.6	10
321	Interventional and pharmacological management of chronic thromboembolic pulmonary hypertension. *Respiratory Medicine*, **2021**, 177, 106293	4.6	2
320	Relationship Between Time From Diagnosis and Morbidity/Mortality in Pulmonary Arterial Hypertension: Results From the Phase III GRIPHON Study. *Chest*, **2021**, 160, 277-286	5.3	4
319	Transplantation for pulmonary arterial hypertension with congenital heart disease: Impact on outcomes of the current therapeutic approach including a high-priority allocation program. *American Journal of Transplantation*, **2021**, 21, 3388-3400	8.7	2
318	Association between Leflunomide and Pulmonary Hypertension. *Annals of the American Thoracic Society*, **2021**, 18, 1306-1315	4.7	0
317	Severe pulmonary hypertension associated with chronic obstructive pulmonary disease: A prospective French multicenter cohort. *Journal of Heart and Lung Transplantation*, **2021**, 40, 1009-1018	5.8	1
316	Effect of riociguat on right ventricular function in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. *Journal of Heart and Lung Transplantation*, **2021**, 40, 1172-1180	5.8	0
315	Three- Versus Two-Drug Therapy for Patients With Newly Diagnosed Pulmonary Arterial Hypertension. *Journal of the American College of Cardiology*, **2021**, 78, 1393-1403	15.1	16

314	Initial combination therapy of macitentan and tadalafil in pulmonary arterial hypertension. *European Respiratory Journal*, **2020**, 56,	13.6	12
313	Phenotype and Outcomes of Pulmonary Hypertension Associated with Neurofibromatosis Type 1. *American Journal of Respiratory and Critical Care Medicine*, **2020**, 202, 843-852	10.2	4
312	Phenotype and outcome of pulmonary arterial hypertension patients carrying a mutation. *European Respiratory Journal*, **2020**, 55,	13.6	11
311	Risk assessment in pulmonary arterial hypertension: Insights from the GRIPHON study. *Journal of Heart and Lung Transplantation*, **2020**, 39, 300-309	5.8	19
310	Sex-specific differences in chronic thromboembolic pulmonary hypertension. Results from the European CTEPH registry. *Journal of Thrombosis and Haemostasis*, **2020**, 18, 151-161	15.4	22
309	Survival Improved in Patients Aged ⩾70 Years With Systemic Sclerosis-Associated Pulmonary Arterial Hypertension During the Period 2006 to 2017 in France. *Chest*, **2020**, 157, 945-954	5.3	5
308	Assessment of the REPLACE study composite endpoint in riociguat-treated patients in the PATENT study. *Pulmonary Circulation*, **2020**, 10, 2045894020973124	2.7	2
307	Comparison of Human and Experimental Pulmonary Veno-Occlusive Disease. *American Journal of Respiratory Cell and Molecular Biology*, **2020**, 63, 118-131	5.7	11
306	Riociguat treatment in patients with pulmonary arterial hypertension: Final safety data from the EXPERT registry. *Respiratory Medicine*, **2020**, 177, 106241	4.6	4
305	Patients with pulmonary arterial hypertension with and without cardiovascular risk factors: Results from the AMBITION trial. *Journal of Heart and Lung Transplantation*, **2019**, 38, 1286-1295	5.8	22
304	Integrating Data From Randomized Controlled Trials and Observational Studies to Assess Survival in Rare Diseases. *Circulation: Cardiovascular Quality and Outcomes*, **2019**, 12, e005095	5.8	5
303	Predictors of survival in patients with not-operated chronic thromboembolic pulmonary hypertension. *Journal of Heart and Lung Transplantation*, **2019**, 38, 833-842	5.8	32
302	French experience of balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension. *European Respiratory Journal*, **2019**, 53,	13.6	82
301	Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial Hypertension. *Circulation*, **2019**, 139, 2440-2450	16.7	32
300	Clinical phenotypes and outcomes of precapillary pulmonary hypertension of sickle cell disease. *European Respiratory Journal*, **2019**, 54,	13.6	8
299	Initial combination therapy with ambrisentan + tadalafil on pulmonary arterial hypertension-related hospitalization in the AMBITION trial. *Journal of Heart and Lung Transplantation*, **2019**, 38, 194-202	5.8	9
298	Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study. *European Journal of Heart Failure*, **2019**, 21, 352-359	12.3	26
297	Haemodynamic definitions and updated clinical classification of pulmonary hypertension. *European Respiratory Journal*, **2019**, 53,	13.6	1412

296	EXPRESS: Switching to riociguat: A potential treatment strategy for the management of CTEPH and PAH. *Pulmonary Circulation*, **2019**, 2045894019837849	2.7	1
295	Association between Rheumatoid Arthritis and Pulmonary Hypertension: Data from the French Pulmonary Hypertension Registry. *Respiration*, **2018**, 95, 244-250	3.7	7
294	Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for Mortality. *Journal of the American College of Cardiology*, **2018**, 71, 752-763	15.1	50
293	RV Fractional Area Change and TAPSE as Predictors of Severe Right Ventricular Dysfunction in Pulmonary Hypertension: A CMR Study. *Lung*, **2018**, 196, 157-164	2.9	22
292	Reply to Frachon: Amphetamine Derivatives and the Risk of Pulmonary Arterial Hypertension: A Missing Chapter of the Story?. *American Journal of Respiratory and Critical Care Medicine*, **2018**, 197, 1364-1365	19.2	
291	Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study. *American Journal of Cardiovascular Drugs*, **2018**, 18, 37-47	4	39
290	Natural History over 8 Years of Pulmonary Vascular Disease in a Patient Carrying Biallelic EIF2AK4 Mutations. *American Journal of Respiratory and Critical Care Medicine*, **2018**, 198, 537-541	10.2	5
289	Pulmonary vascular remodeling patterns and expression of general control nonderepressible 2 (GCN2) in pulmonary veno-occlusive disease. *Journal of Heart and Lung Transplantation*, **2018**, 37, 647-655	5.8	31
288	Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI) Receptor Agonist in Pulmonary Arterial Hypertension (GRIPHON) study. *Journal of Heart and Lung Transplantation*, **2018**, 37, 401-408	5.8	12
287	Prognostic Value of Follow-Up Hemodynamic Variables After Initial Management in Pulmonary Arterial Hypertension. *Circulation*, **2018**, 137, 693-704	16.7	92
286	Pulmonary Arterial Hypertension Associated With Systemic Lupus Erythematosus: Results From the French Pulmonary Hypertension Registry. *Chest*, **2018**, 153, 143-151	5.3	35
285	Clinical and Hemodynamic Correlates of Pulmonary Arterial Stiffness in Incident, Untreated Patients With Idiopathic Pulmonary Arterial Hypertension. *Chest*, **2018**, 154, 882-892	5.3	7
284	Impact of the initiation of balloon pulmonary angioplasty program on referral of patients with chronic thromboembolic pulmonary hypertension to surgery. *Journal of Heart and Lung Transplantation*, **2018**, 37, 1102-1110	5.8	15
283	Association between six-minute walk distance and long-term outcomes in patients with pulmonary arterial hypertension: Data from the randomized SERAPHIN trial. *PLoS ONE*, **2018**, 13, e0193226	3.7	17
282	Chronic blood exchange transfusions in the management of pre-capillary pulmonary hypertension complicating sickle cell disease. *European Respiratory Journal*, **2018**, 52,	13.6	15
281	Haemodynamics and serial risk assessment in systemic sclerosis associated pulmonary arterial hypertension. *European Respiratory Journal*, **2018**, 52,	13.6	37
280	Poor Subpleural Perfusion Predicts Failure After Balloon Pulmonary Angioplasty for Nonoperable Chronic Thromboembolic Pulmonary Hypertension. *Chest*, **2018**, 154, 521-531	5.3	17
279	Clinical phenotypes and survival of pre-capillary pulmonary hypertension in systemic sclerosis. *PLoS ONE*, **2018**, 13, e0197112	3.7	24

278	Factors predicting outcome after pulmonary endarterectomy. *PLoS ONE*, **2018**, 13, e0198198	3.7	16
277	Association Between BMI and Obesity With Survival in Pulmonary Arterial Hypertension. *Chest*, **2018**, 154, 872-881	5.3	22
276	Snoring and Obstructive Sleep Apnea: Objective Efficacy and Impact of a Chairside Fabricated Mandibular Advancement Device. *Journal of Prosthodontics*, **2017**, 26, 381-386	3.9	6
275	Clinical phenotypes and outcomes of heritable and sporadic pulmonary veno-occlusive disease: a population-based study. *Lancet Respiratory Medicine,the*, **2017**, 5, 125-134	35.1	76
274	Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial. *Annals of the Rheumatic Diseases*, **2017**, 76, 1219-1227	2.4	96
273	Hypermethylation of BMPR2 Promoter Occurs in Patients with Heritable Pulmonary Arterial Hypertension and Inhibits BMPR2 Expression. *American Journal of Respiratory and Critical Care Medicine*, **2017**, 196, 925-928	10.2	30
272	Haemodynamic effects of riociguat in inoperable/recurrent chronic thromboembolic pulmonary hypertension. *Heart*, **2017**, 103, 599-606	5.1	19
271	Plasma proteome analysis in patients with pulmonary arterial hypertension: an observational cohort study. *Lancet Respiratory Medicine,the*, **2017**, 5, 717-726	35.1	62
270	Impact of High-Priority Allocation on Lung and Heart-Lung Transplantation for Pulmonary Hypertension. *Annals of Thoracic Surgery*, **2017**, 104, 404-411	2.7	15
269	Dead-space ventilation is linked to exercise capacity and survival in distal chronic thromboembolic pulmonary hypertension. *Journal of Heart and Lung Transplantation*, **2017**, 36, 1234-1242	5.8	25
268	Use of Blockers in Pulmonary Hypertension. *Circulation: Heart Failure*, **2017**, 10,	7.6	41
267	The pathophysiology of chronic thromboembolic pulmonary hypertension. *European Respiratory Review*, **2017**, 26,	9.8	187
266	Rationale and study design of RESPITE: An open-label, phase 3b study of riociguat in patients with pulmonary arterial hypertension who demonstrate an insufficient response to treatment with phosphodiesterase-5 inhibitors. *Respiratory Medicine*, **2017**, 122 Suppl 1, S18-S22	4.6	13
265	Long-term outcome in liver transplantation candidates with portopulmonary hypertension. *Hepatology*, **2017**, 65, 1683-1692	11.2	40
264	Diagnosis and Classification of 17 Diseases from 1404 Subjects via Pattern Analysis of Exhaled Molecules. *ACS Nano*, **2017**, 11, 112-125	16.7	279
263	Riociguat in patients with chronic thromboembolic pulmonary hypertension: results from an early access study. *BMC Pulmonary Medicine*, **2017**, 17, 216	3.5	17
262	Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension. *European Respiratory Journal*, **2017**, 50,	13.6	58
261	Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study. *Lancet Respiratory Medicine,the*, **2017**, 5, 785-794	35.1	133

260	RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors. *European Respiratory Journal*, **2017**, 50,	13.6	74
259	Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study. *European Respiratory Journal*, **2017**, 50,	13.6	62
258	Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. *European Respiratory Journal*, **2017**, 50,	13.6	298
257	Acute decompensated pulmonary hypertension. *European Respiratory Review*, **2017**, 26,	9.8	28
256	A Clinical and Echocardiographic Score to Identify Pulmonary Hypertension Due to HFpEF. *Journal of Cardiac Failure*, **2017**, 23, 29-35	3.3	14
255	Long-term outcomes of pulmonary arterial hypertension under specific drug therapy in Eisenmenger syndrome. *Journal of Heart and Lung Transplantation*, **2017**, 36, 386-398	5.8	12
254	Non-invasive diagnosis of pulmonary hypertension from lung Doppler signal: a proof of concept study. *Journal of Clinical Monitoring and Computing*, **2017**, 31, 903-910	2	3
253	Macitentan Improves Health-Related Quality´of Life for Patients With Pulmonary Arterial Hypertension: Results From the Randomized Controlled SERAPHIN Trial. *Chest*, **2017**, 151, 106-118	5.3	36
252	SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension. *European Heart Journal*, **2017**, 38, 1147-1155	9.5	44
251	The changing landscape of chronic thromboembolic pulmonary hypertension management. *European Respiratory Review*, **2017**, 26,	9.8	50
250	Pulmonary endothelial cell DNA methylation signature in pulmonary arterial hypertension. *Oncotarget*, **2017**, 8, 52995-53016	3.3	30
249	2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung	9.5	3455
248	A prospective study of the 6 min walk test as a surrogate marker for haemodynamics in two independent cohorts of treatment-naïve systemic sclerosis-associated pulmonary arterial hypertension. *Annals of the Rheumatic Diseases*, **2016**, 75, 1457-65	2.4	9
247	Future Directions in Chronic Thromboembolic Pulmonary Hypertension. Disease at a Crossroads?. *Annals of the American Thoracic Society*, **2016**, 13 Suppl 3, S255-8	4.7	6
246	Resting pulmonary artery pressure of 21-24 mmHg predicts abnormal exercise haemodynamics. *European Respiratory Journal*, **2016**, 47, 1436-44	13.6	31
245	Loss of Vascular Distensibility During Exercise Is an Early Hemodynamic Marker of Pulmonary Vascular Disease. *Chest*, **2016**, 149, 353-361	5.3	46
244	Guía ESC/ERS 2015 sobre diagnóstico y tratamiento de la hipertensión pulmonar. *Revista Espanola De Cardiologia*, **2016**, 69, 177.e1-177.e62	1.5	137
243	Long-Term Outcome of Patients With Chronic Thromboembolic Pulmonary Hypertension: Results From an International Prospective Registry. *Circulation*, **2016**, 133, 859-71	16.7	331

242	Potassium Channel Subfamily K Member 3 (KCNK3) Contributes to the Development of Pulmonary Arterial Hypertension. *Circulation*, **2016**, 133, 1371-85	16.7	98
241	Comparative Safety and Tolerability of Prostacyclins in Pulmonary Hypertension. *Drug Safety*, **2016**, 39, 287-94	5.1	26
240	Genetic counselling in a national referral centre for pulmonary hypertension. *European Respiratory Journal*, **2016**, 47, 541-52	13.6	63
239	Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension. *Journal of Clinical Investigation*, **2016**, 126, 3207-18	15.9	144
238	Quality of life in patients with chronic thromboembolic pulmonary hypertension. *European Respiratory Journal*, **2016**, 48, 526-37	13.6	34
237	Future perspectives in pulmonary arterial hypertension. *European Respiratory Review*, **2016**, 25, 381-389	9.8	14
236	BMPR2 mutation status influences bronchial vascular changes in pulmonary arterial hypertension. *European Respiratory Journal*, **2016**, 48, 1668-1681	13.6	49
235	Pulmonary veno-occlusive disease. *European Respiratory Journal*, **2016**, 47, 1518-34	13.6	134
234	Initial dual oral combination therapy in pulmonary arterial hypertension. *European Respiratory Journal*, **2016**, 47, 1727-36	13.6	85
233	Lung capillary blood volume and membrane diffusion in precapillary pulmonary hypertension. *Journal of Heart and Lung Transplantation*, **2016**, 35, 647-56	5.8	6
232	BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis. *Lancet Respiratory Medicine,the*, **2016**, 4, 129-37	35.1	202
231	Predictors of long-term outcomes in patients treated with riociguat for chronic thromboembolic pulmonary hypertension: data from the CHEST-2 open-label, randomised, long-term extension trial. *Lancet Respiratory Medicine,the*, **2016**, 4, 372-80	35.1	98
230	Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION study. *Lancet Respiratory Medicine,the*, **2016**, 4, 894-901	35.1	37
229	Endothelial-to-mesenchymal transition in pulmonary hypertension. *Circulation*, **2015**, 131, 1006-18	16.7	320
228	Palliative Potts shunt for the treatment of children with drug-refractory pulmonary arterial hypertension: updated data from the first 24 patients. *European Journal of Cardio-thoracic Surgery*, **2015**, 47, e105-10	3	93
227	Usefulness of Cardiovascular Magnetic Resonance Indices to Rule In or Rule Out Precapillary Pulmonary Hypertension. *Canadian Journal of Cardiology*, **2015**, 31, 1469-76	3.8	5
226	Use of responder threshold criteria to evaluate the response to treatment in the phase III CHEST-1 study. *Journal of Heart and Lung Transplantation*, **2015**, 34, 348-55	5.8	11
225	Mitomycin-Induced Pulmonary Veno-Occlusive Disease: Evidence From Human Disease and Animal Models. *Circulation*, **2015**, 132, 834-47	16.7	80

224	Safety of therapeutic doses of tinzaparin during pregnancy. *Gynecologic and Obstetric Investigation*, **2015**, 79, 256-62	2.5	3
223	Validation of two predictive models for survival in pulmonary arterial hypertension. *European Respiratory Journal*, **2015**, 46, 152-64	13.6	62
222	New pharmacotherapy options for pulmonary arterial hypertension. *Expert Opinion on Pharmacotherapy*, **2015**, 16, 2113-31	4	17
221	2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung	13.6	1672
220	Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. *New England Journal of Medicine*, **2015**, 373, 834-44	59.2	618
219	Occupational exposure to organic solvents: a risk factor for pulmonary veno-occlusive disease. *European Respiratory Journal*, **2015**, 46, 1721-31	13.6	55
218	Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2). *European Respiratory Journal*, **2015**, 45, 1293-302	13.6	175
217	Effect of macitentan on hospitalizations: results from the SERAPHIN trial. *JACC: Heart Failure*, **2015**, 3, 1-8	7.9	42
216	Clinical pharmacology of endothelin receptor antagonists used in the treatment of pulmonary arterial hypertension. *American Journal of Cardiovascular Drugs*, **2015**, 15, 13-26	4	19
215	Characteristics of pulmonary arterial hypertension in affected carriers of a mutation located in the cytoplasmic tail of bone morphogenetic protein receptor type 2. *Chest*, **2015**, 147, 1385-1394	5.3	26
214	Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN. *European Respiratory Journal*, **2015**, 46, 1711-20	13.6	31
213	Pulmonary Hypertension Complicating Fibrosing Mediastinitis. *Medicine (United States)*, **2015**, 94, e1800	1.8	32
212	Nasal decongestant exposure in patients with pulmonary arterial hypertension: a pilot study. *European Respiratory Journal*, **2015**, 46, 1211-4	13.6	3
211	Chronic thromboembolic pulmonary hypertension. *Presse Medicale*, **2015**, 44, e409-16	2.2	15
210	Selexipag for the Treatment of Pulmonary Arterial Hypertension. *New England Journal of Medicine*, **2015**, 373, 2522-33	59.2	521
209	Long-term safety and efficacy of imatinib in pulmonary arterial hypertension. *Journal of Heart and Lung Transplantation*, **2015**, 34, 1366-75	5.8	72
208	Response to Letter Regarding Article, "Advances in Therapeutic Interventions for Patients With Pulmonary Arterial Hypertension". *Circulation*, **2015**, 132, e154	16.7	3
207	Nebivolol for improving endothelial dysfunction, pulmonary vascular remodeling, and right heart function in pulmonary hypertension. *Journal of the American College of Cardiology*, **2015**, 65, 668-80	15.1	101

206	Chemotherapy-induced pulmonary hypertension: role of alkylating agents. *American Journal of Pathology*, **2015**, 185, 356-71	5.8	116
205	EIF2AK4 mutations cause pulmonary veno-occlusive disease, a recessive form of pulmonary hypertension. *Nature Genetics*, **2014**, 46, 65-9	36.3	259
204	Targeted therapies in pulmonary arterial hypertension. *Pharmacology & Therapeutics*, **2014**, 141, 172-91	13.9	128
203	Proinflammatory cytokine levels are linked to death in pulmonary arterial hypertension. *European Respiratory Journal*, **2014**, 43, 915-7	13.6	76
202	N-acetylcysteine improves established monocrotaline-induced pulmonary hypertension in rats. *Respiratory Research*, **2014**, 15, 65	7.3	34
201	Current epoprostenol use in patients with severe idiopathic, heritable or anorexigen-associated pulmonary arterial hypertension: data from the French pulmonary hypertension registry. *International Journal of Cardiology*, **2014**, 172, 561-7	3.2	24
200	EPITOME-2: An open-label study assessing the transition to a new formulation of intravenous epoprostenol in patients with pulmonary arterial hypertension. *American Heart Journal*, **2014**, 167, 210-7	4.9	46
199	The potential for macitentan, a new dual endothelin receptor antagonist, in the treatment of pulmonary arterial hypertension. *Therapeutic Advances in Respiratory Disease*, **2014**, 8, 84-92	4.9	7
198	Prevalence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism. Prevalence of CTEPH after pulmonary embolism. *Thrombosis and Haemostasis*, **2014**, 112, 598-605	7	194
197	Key role of the endothelial TGF-β/ALK1/endoglin signaling pathway in humans and rodents pulmonary hypertension. *PLoS ONE*, **2014**, 9, e100310	3.7	67
196	Mechanisms of exertional dyspnoea in pulmonary veno-occlusive disease with EIF2AK4 mutations. *European Respiratory Journal*, **2014**, 44, 1069-72	13.6	33
195	Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study. *European Respiratory Journal*, **2014**, 43, 1691-7	13.6	214
194	Advances in therapeutic interventions for patients with pulmonary arterial hypertension. *Circulation*, **2014**, 130, 2189-208	16.7	209
193	Microvascular disease in chronic thromboembolic pulmonary hypertension: a role for pulmonary veins and systemic vasculature. *European Respiratory Journal*, **2014**, 44, 1275-88	13.6	135
192	Pulmonary arterial hypertension in patients treated with interferon. *European Respiratory Journal*, **2014**, 44, 1627-34	13.6	66
191	Chronic thromboembolic pulmonary hypertension complicating long-term cyproterone acetate therapy. *European Respiratory Review*, **2014**, 23, 260-3	9.8	2
190	Long-term sildenafil added to intravenous epoprostenol in patients with pulmonary arterial hypertension. *Journal of Heart and Lung Transplantation*, **2014**, 33, 689-97	5.8	14
189	Reply: pulmonary hypertension of sickle cell disease beyond classification constraints. *Journal of the American College of Cardiology*, **2014**, 63, 2882-3	15.1	3

188	Long-term results from the EARLY study of bosentan in WHO functional class II pulmonary arterial hypertension patients. *International Journal of Cardiology*, **2014**, 172, 332-9	3.2	34
187	Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. *New England Journal of Medicine*, **2013**, 369, 319-29	59.2	852
186	Pharmacokinetic evaluation of sildenafil as a pulmonary hypertension treatment. *Expert Opinion on Drug Metabolism and Toxicology*, **2013**, 9, 1193-205	5.5	19
185	Macitentan and morbidity and mortality in pulmonary arterial hypertension. *New England Journal of Medicine*, **2013**, 369, 809-18	59.2	878
184	Pulmonary hypertension due to left heart diseases. *Journal of the American College of Cardiology*, **2013**, 62, D100-8	15.1	437
183	Updated clinical classification of pulmonary hypertension. *Journal of the American College of Cardiology*, **2013**, 62, D34-41	15.1	1937
182	Pulmonary hypertension in chronic lung diseases. *Journal of the American College of Cardiology*, **2013**, 62, D109-16	15.1	390
181	Pulmonary arterial hypertension. *Orphanet Journal of Rare Diseases*, **2013**, 8, 97	4.2	168
180	Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. *Circulation*, **2013**, 127, 1128-38	16.7	368
179	A proof of concept for the detection and classification of pulmonary arterial hypertension through breath analysis with a sensor array. *American Journal of Respiratory and Critical Care Medicine*, **2013**, 188, 756-9	10.2	37
178	Riociguat for pulmonary hypertension. *New England Journal of Medicine*, **2013**, 369, 2268	59.2	13
177	Genome-wide association analysis identifies a susceptibility locus for pulmonary arterial hypertension. *Nature Genetics*, **2013**, 45, 518-21	36.3	82
176	Cytotoxic cells and granulysin in pulmonary arterial hypertension and pulmonary veno-occlusive disease. *American Journal of Respiratory and Critical Care Medicine*, **2013**, 187, 189-96	10.2	42
175	Efficacy, safety and pharmacokinetics of bosentan in portopulmonary hypertension. *European Respiratory Journal*, **2013**, 41, 96-103	13.6	75
174	Vascular and right ventricular remodelling in chronic thromboembolic pulmonary hypertension. *European Respiratory Journal*, **2013**, 41, 224-32	13.6	78
173	Drug-induced pulmonary arterial hypertension: a recent outbreak. *European Respiratory Review*, **2013**, 22, 244-50	9.8	67
172	Chronic thromboembolic pulmonary hypertension: role of medical therapy. *European Respiratory Journal*, **2013**, 41, 985-90	13.6	72
171	Survival in systemic sclerosis-associated pulmonary arterial hypertension in the modern management era. *Annals of the Rheumatic Diseases*, **2013**, 72, 1940-6	2.4	89

170	Out-of-proportion pulmonary hypertension and heart failure with preserved ejection fraction. *Respiration*, **2013**, 85, 471-7	3.7	19
169	Renal replacement therapy in patients with severe precapillary pulmonary hypertension with acute right heart failure. *Respiration*, **2013**, 85, 464-70	3.7	12
168	Therapies for pulmonary arterial hypertension: where are we today, where do we go tomorrow?. *European Respiratory Review*, **2013**, 22, 217-26	9.8	55
167	Estimating right ventricular stroke work and the pulsatile work fraction in pulmonary hypertension. *Chest*, **2013**, 143, 1343-1350	5.3	30
166	Left ventricular ejection time in acute heart failure complicating precapillary pulmonary hypertension. *Chest*, **2013**, 144, 1512-1520	5.3	18
165	The need to move from 6-minute walk distance to outcome trials in pulmonary arterial hypertension. *European Respiratory Review*, **2013**, 22, 487-94	9.8	30
164	Factors associated with diagnosis and operability of chronic thromboembolic pulmonary hypertension. A case-control study. *Thrombosis and Haemostasis*, **2013**, 110, 83-91	7	77
163	The beneficial effect of suramin on monocrotaline-induced pulmonary hypertension in rats. *PLoS ONE*, **2013**, 8, e77073	3.7	9
162	Tadalafil for the treatment of pulmonary arterial hypertension: a double-blind 52-week uncontrolled extension study. *Journal of the American College of Cardiology*, **2012**, 60, 768-74	15.1	101
161	Dysregulated renin-angiotensin-aldosterone system contributes to pulmonary arterial hypertension. *American Journal of Respiratory and Critical Care Medicine*, **2012**, 186, 780-9	10.2	244
160	Potts shunt in children with idiopathic pulmonary arterial hypertension: long-term results. *Annals of Thoracic Surgery*, **2012**, 94, 817-24	2.7	93
159	Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: an observational study. *Journal of Heart and Lung Transplantation*, **2012**, 31, 150-8	5.8	73
158	Pre-implantation genetic diagnosis in pulmonary arterial hypertension due to BMPR2 mutation. *European Respiratory Journal*, **2012**, 39, 1534-5	13.6	32
157	The study of risk in pulmonary arterial hypertension. *European Respiratory Review*, **2012**, 21, 234-8	9.8	14
156	Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. *European Respiratory Journal*, **2012**, 40, 874-80	13.6	203
155	Pulmonary arterial hypertension in patients treated by dasatinib. *Circulation*, **2012**, 125, 2128-37	16.7	448
154	Pulmonary hypertension in lymphangioleiomyomatosis: characteristics in 20 patients. *European Respiratory Journal*, **2012**, 40, 630-40	13.6	58
153	IgG from patients with pulmonary arterial hypertension and/or systemic sclerosis binds to vascular smooth muscle cells and induces cell contraction. *Annals of the Rheumatic Diseases*, **2012**, 71, 596-605	2.4	32

152	Pulmonary hypertension associated with benfluorex exposure. *European Respiratory Journal*, **2012**, 40, 1164-72	13.6	60
151	Ventilation/perfusion lung scan in pulmonary veno-occlusive disease. *European Respiratory Journal*, **2012**, 40, 75-83	13.6	39
150	Human Immunodeficiency Virus nef signature sequences are associated with pulmonary hypertension. *AIDS Research and Human Retroviruses*, **2012**, 28, 607-18	1.6	42
149	Updated Clinical Classification of Pulmonary Hypertension. *Progress in Respiratory Research*, **2012**, 1-13		
148	Pulmonary Hypertension in Sickle Cell Disease. *Progress in Respiratory Research*, **2012**, 137-142		
147	EBUS-TBNA in the differential diagnosis of pulmonary artery sarcoma and thromboembolism. *European Respiratory Journal*, **2012**, 39, 1549-50	13.6	9
146	Independent association of urinary F2-isoprostanes with survival in pulmonary arterial hypertension. *Chest*, **2012**, 142, 869-876	5.3	40
145	Pulmonary Langerhans cell histiocytosis-associated pulmonary hypertension: clinical characteristics and impact of pulmonary arterial hypertension therapies. *Chest*, **2012**, 142, 1150-1157	5.3	79
144	Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension. *Journal of Heart and Lung Transplantation*, **2011**, 30, 632-43	5.8	79
143	Pulmonary veno-occlusive disease: the bête noire of pulmonary hypertension in connective tissue diseases?. *Presse Medicale*, **2011**, 40, e65-78	2.2	21
142	Endothelin receptor antagonists for the treatment of pulmonary arterial hypertension. *Expert Opinion on Pharmacotherapy*, **2011**, 12, 1585-96	4	19
141	Surgical management and outcome of patients with chronic thromboembolic pulmonary hypertension: results from an international prospective registry. *Journal of Thoracic and Cardiovascular Surgery*, **2011**, 141, 702-10	1.5	454
140	Pulmonary hypertension in patients with neurofibromatosis type I. *Medicine (United States)*, **2011**, 90, 201-211	1.8	42
139	Increased oxidative stress and severe arterial remodeling induced by permanent high-flow challenge in experimental pulmonary hypertension. *Respiratory Research*, **2011**, 12, 119	7.3	64
138	Systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease: impact of pulmonary arterial hypertension therapies. *Arthritis and Rheumatism*, **2011**, 63, 2456-64		87
137	Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival. *Arthritis and Rheumatism*, **2011**, 63, 3522-30		199
136	Autocrine fibroblast growth factor-2 signaling contributes to altered endothelial phenotype in pulmonary hypertension. *American Journal of Respiratory Cell and Molecular Biology*, **2011**, 45, 311-22	5.7	98
135	Corrigendum to: 'Guidelines for the diagnosis and treatment of pulmonary hypertension' [European Heart Journal (2009) 30, 2493-2537]. The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). *European Heart Journal*, **2011**, 32, 926-926	9.5	3

134	C-kit-positive cells accumulate in remodeled vessels of idiopathic pulmonary arterial hypertension. *American Journal of Respiratory and Critical Care Medicine*, **2011**, 184, 116-23	10.2	147
133	Treatment of pulmonary arterial hypertension with targeted therapies. *Nature Reviews Cardiology*, **2011**, 8, 526-38	14.8	102
132	Chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry. *Circulation*, **2011**, 124, 1973-81	16.7	630
131	A hemodynamic study of pulmonary hypertension in sickle cell disease. *New England Journal of Medicine*, **2011**, 365, 44-53	59.2	354
130	Pulmonary arterial hypertension in a patient with Cowden syndrome and anorexigen exposure. *Chest*, **2011**, 140, 1066-1068	5.3	6
129	Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study. *Chest*, **2011**, 140, 1274-1283	5.3	187
128	Pulmonary hypertension associated with portal hypertension **2011**, 245-250		
127	Pulmonary hypertension related to appetite suppressants **2011**, 236-244		
126	Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil. *Rheumatology*, **2010**, 49, 490-500	3.9	74
125	Pulmonary arterial hypertension associated with systemic sclerosis in patients with functional class II dyspnoea: mild symptoms but severe outcome. *Rheumatology*, **2010**, 49, 940-4	3.9	44
124	Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension. *European Heart Journal*, **2010**, 31, 1898-907	9.5	139
123	Vasodilators in patients with chronic obstructive pulmonary disease and pulmonary hypertension: not ready for prime time!. *American Journal of Respiratory and Critical Care Medicine*, **2010**, 181, 202-3	10.2	10
122	Classification de l'hypertension pulmonaire. *Archives of Cardiovascular Diseases Supplements*, **2010**, 2, 132-136	0.3	
121	Clinical outcomes of pulmonary arterial hypertension in patients carrying an ACVRL1 (ALK1) mutation. *American Journal of Respiratory and Critical Care Medicine*, **2010**, 181, 851-61	10.2	209
120	Pulmonary veno-occlusive disease: recent progress and current challenges. *Respiratory Medicine*, **2010**, 104 Suppl 1, S23-32	4.6	78
119	Evidence for the use of combination targeted therapeutic approaches for the management of pulmonary arterial hypertension. *Respiratory Medicine*, **2010**, 104 Suppl 1, S74-80	4.6	9
118	Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. *Circulation*, **2010**, 122, 156-63	16.7	1035
117	HIV-associated pulmonary arterial hypertension: survival and prognostic factors in the modern therapeutic era. *Aids*, **2010**, 24, 67-75	3.5	118

116	Characterization of pulmonary arterial hypertension patients walking more than 450 m in 6 min at diagnosis. *Chest*, **2010**, 137, 1297-303	5.3	38
115	Clinical worsening in trials of pulmonary arterial hypertension: results and implications. *Current Opinion in Pulmonary Medicine*, **2010**, 16 Suppl 1, S11-9	3	30
114	Perspective on the optimal endpoints for pulmonary arterial hypertension trials. *Current Opinion in Pulmonary Medicine*, **2010**, 16 Suppl 1, S43-6	3	9
113	Assessing effectiveness of pulmonary arterial hypertension therapies in daily practice. *Current Opinion in Pulmonary Medicine*, **2010**, 16 Suppl 1, S21-6	3	3
112	Long-term outcome of double-lung and heart-lung transplantation for pulmonary hypertension: a comparative retrospective study of 219 patients. *European Journal of Cardio-thoracic Surgery*, **2010**, 38, 277-84	3	94
111	Absence of influence of gender and BMPR2 mutation type on clinical phenotypes of pulmonary arterial hypertension. *Respiratory Research*, **2010**, 11, 73	7.3	66
110	Stress Doppler echocardiography in relatives of patients with idiopathic and familial pulmonary arterial hypertension: results of a multicenter European analysis of pulmonary artery pressure response to exercise and hypoxia. *Circulation*, **2009**, 119, 1747-57	16.7	164
109	Evaluation of various empirical formulas for estimating mean pulmonary artery pressure by using systolic pulmonary artery pressure in adults. *Chest*, **2009**, 135, 760-768	5.3	83
108	Idiopathic pulmonary arterial hypertension and pulmonary veno-occlusive disease: similarities and differences. *Seminars in Respiratory and Critical Care Medicine*, **2009**, 30, 411-20	3.9	28
107	Pulmonary arterial hypertension and HIV infection. *Seminars in Respiratory and Critical Care Medicine*, **2009**, 30, 440-7	3.9	16
106	Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension. *Advances in Therapy*, **2009**, 26, 813-25	4.1	75
105	Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). *European Heart Journal*, **2009**, 30, 2493-537	9.5	2531
104	Updated clinical classification of pulmonary hypertension. *Journal of the American College of Cardiology*, **2009**, 54, S43-S54	15.1	1640
103	Future perspectives for the treatment of pulmonary arterial hypertension. *Journal of the American College of Cardiology*, **2009**, 54, S108-S117	15.1	50
102	Guía de práctica clínica para el diagnóstico y tratamiento de la hipertensión pulmonar. *Revista Espanola De Cardiologia (English Ed)*, **2009**, 62, 1464.e1-1464.e58	0.7	1
101	Tadalafil therapy for pulmonary arterial hypertension. *Circulation*, **2009**, 119, 2894-903	16.7	769
100	Guía de práctica clínica para el diagnóstico y tratamiento de la hipertensión pulmonar. *Revista Espanola De Cardiologia*, **2009**, 62, 1464.e1-1464.e58	1.5	3
99	Endothelial-derived FGF2 contributes to the progression of pulmonary hypertension in humans and rodents. *Journal of Clinical Investigation*, **2009**, 119, 512-23	15.9	148

98	Is pulmonary arterial hypertension really a late complication of systemic sclerosis?. *Chest*, **2009**, 136, 1211-1219	5.3	100
97	Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial. *Journal of the American College of Cardiology*, **2008**, 52, 2127-34	15.1	409
96	Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. *American Journal of Respiratory and Critical Care Medicine*, **2008**, 178, 81-8	10.2	336
95	Therapeutic advances in pulmonary arterial hypertension. *Therapeutic Advances in Respiratory Disease*, **2008**, 2, 249-65	4.9	30
94	Bosentan in mild pulmonary hypertension □Authors' reply. *Lancet, The*, **2008**, 372, 1731-1732	40	
93	Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era. *American Journal of Respiratory and Critical Care Medicine*, **2008**, 177, 108-13	10.2	324
92	Clinical outcomes of pulmonary arterial hypertension in carriers of BMPR2 mutation. *American Journal of Respiratory and Critical Care Medicine*, **2008**, 177, 1377-83	10.2	225
91	Portopulmonary hypertension: survival and prognostic factors. *American Journal of Respiratory and Critical Care Medicine*, **2008**, 178, 637-43	10.2	175
90	Pulmonary veno-occlusive disease: clinical, functional, radiologic, and hemodynamic characteristics and outcome of 24 cases confirmed by histology. *Medicine (United States)*, **2008**, 87, 220-233	1.8	229
89	Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. *Annals of Internal Medicine*, **2008**, 149, 521-30	8	437
88	Pulmonary arterial hypertension and its association with HIV infection: an overview. *Aids*, **2008**, 22 Suppl 3, S1-6	3.5	18
87	Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases. *Arthritis and Rheumatism*, **2008**, 58, 521-31		261
86	The French registry of pulmonary arterial hypertension in children: rationale and design. *Current Medical Research and Opinion*, **2007**, 23, S27-S33	2.5	4
85	Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. *Chest*, **2007**, 131, 1917-28	5.3	421
84	Role of endothelium-derived CC chemokine ligand 2 in idiopathic pulmonary arterial hypertension. *American Journal of Respiratory and Critical Care Medicine*, **2007**, 176, 1041-7	10.2	173
83	Pulmonary arterial hypertension: a rare complication of primary Sjögren syndrome: report of 9 new cases and review of the literature. *Medicine (United States)*, **2007**, 86, 299-315	1.8	118
82	Endothelin-1/endothelin-3 ratio: a potential prognostic factor of pulmonary arterial hypertension. *Chest*, **2007**, 131, 101-8	5.3	53
81	Rapid switch from intravenous epoprostenol to intravenous treprostinil in patients with pulmonary arterial hypertension. *Journal of Cardiovascular Pharmacology*, **2007**, 49, 1-5	3.1	67

80	Diagnostic value of D-dimer in patients with suspected pulmonary embolism: results from a multicentre outcome study. *Thrombosis Research*, **2007**, 120, 195-200	8.2	25
79	Intravenous epoprostenol in inoperable chronic thromboembolic pulmonary hypertension. *Journal of Heart and Lung Transplantation*, **2007**, 26, 357-62	5.8	105
78	Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases. *Human Pathology*, **2007**, 38, 893-902	3.7	238
77	Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. *Journal of Rheumatology*, **2007**, 34, 2417-22	4.1	128
76	Mutations of the TGF-beta type II receptor BMPR2 in pulmonary arterial hypertension. *Human Mutation*, **2006**, 27, 121-32	4.7	322
75	BMPR2 gene rearrangements account for a significant proportion of mutations in familial and idiopathic pulmonary arterial hypertension. *Human Mutation*, **2006**, 27, 212-3	4.7	173
74	Serotonin transporter polymorphisms in familial and idiopathic pulmonary arterial hypertension. *American Journal of Respiratory and Critical Care Medicine*, **2006**, 173, 798-802	10.2	76
73	Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. *European Heart Journal*, **2006**, 27, 589-95	9.5	224
72	Controversies, uncertainties and future research on the treatment of chronic thromboembolic pulmonary hypertension. *Proceedings of the American Thoracic Society*, **2006**, 3, 608-14		65
71	Angiopoietin/Tie2 pathway influences smooth muscle hyperplasia in idiopathic pulmonary hypertension. *American Journal of Respiratory and Critical Care Medicine*, **2006**, 174, 1025-33	10.2	95
70	The Need for National Registries in Rare Diseases. *American Journal of Respiratory and Critical Care Medicine*, **2006**, 174, 228a-229	10.2	1
69	Chronic thromboembolic pulmonary hypertension. *Circulation*, **2006**, 113, 2011-20	16.7	413
68	Cross talk between endothelial and smooth muscle cells in pulmonary hypertension: critical role for serotonin-induced smooth muscle hyperplasia. *Circulation*, **2006**, 113, 1857-64	16.7	217
67	Current understanding of the role of bosentan in inoperable chronic thromboembolic pulmonary hypertension. *Expert Opinion on Pharmacotherapy*, **2006**, 7, 1133-8	4	1
66	Pulmonary arterial hypertension in France: results from a national registry. *American Journal of Respiratory and Critical Care Medicine*, **2006**, 173, 1023-30	10.2	1367
65	Current and future management of chronic thromboembolic pulmonary hypertension: from diagnosis to treatment responses. *Proceedings of the American Thoracic Society*, **2006**, 3, 601-7		34
64	Deleterious effects of beta-blockers on exercise capacity and hemodynamics in patients with portopulmonary hypertension. *Gastroenterology*, **2006**, 130, 120-6	13.3	240
63	Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension. *Chest*, **2006**, 130, 182-9	5.3	254

62	Sildenafil citrate therapy for pulmonary arterial hypertension. *New England Journal of Medicine*, **2005**, 353, 2148-57	59.2	1843
61	Ambrisentan therapy for pulmonary arterial hypertension. *Journal of the American College of Cardiology*, **2005**, 46, 529-35	15.1	364
60	New Formula for Predicting Mean Pulmonary Artery Pressure. *Chest*, **2005**, 128, 467	5.3	3
59	Serotonin transporter and receptors in various forms of human pulmonary hypertension. *Chest*, **2005**, 128, 552S-553S	5.3	13
58	Pulmonary endothelin-1 clearance in human pulmonary arterial hypertension. *Chest*, **2005**, 128, 622S	5.3	19
57	Severe pulmonary hypertension during pregnancy: mode of delivery and anesthetic management of 15 consecutive cases. *Anesthesiology*, **2005**, 102, 1133-7; discussion 5A-6A	4.3	234
56	Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. *Circulation*, **2005**, 111, 3105-11	16.7	815
55	Drug Insight: endothelin-receptor antagonists for pulmonary arterial hypertension in systemic rheumatic diseases. *Nature Clinical Practice Rheumatology*, **2005**, 1, 93-101		13
54	Treatment of pulmonary arterial hypertension with bosentan: from pathophysiology to clinical evidence. *Expert Opinion on Pharmacotherapy*, **2005**, 6, 1337-48	4	12
53	Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. *American Journal of Respiratory and Critical Care Medicine*, **2004**, 170, 1212-7	10.2	192
52	Pulmonary hypertension: CT of the chest in pulmonary venoocclusive disease. *American Journal of Roentgenology*, **2004**, 183, 65-70	5.4	190
51	Sildenafil for pulmonary arterial hypertension: still waiting for evidence. *American Journal of Respiratory and Critical Care Medicine*, **2004**, 169, 6-7	10.2	17
50	New formula for predicting mean pulmonary artery pressure using systolic pulmonary artery pressure. *Chest*, **2004**, 126, 1313-7	5.3	831
49	Serotonin-induced smooth muscle hyperplasia in various forms of human pulmonary hypertension. *Circulation Research*, **2004**, 94, 1263-70	15.7	163
48	Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. *European Heart Journal*, **2004**, 25, 2243-78	9.5	665
47	Clinical classification of pulmonary hypertension. *Journal of the American College of Cardiology*, **2004**, 43, 5S-12S	15.1	1162
46	Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension. *Journal of the American College of Cardiology*, **2004**, 43, 81S-88S	15.1	137
45	Treatment of pulmonary arterial hypertension. *New England Journal of Medicine*, **2004**, 351, 1425-36	59.2	1338

44	Surgical treatments/interventions for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. *Chest*, **2004**, 126, 63S-71S	5.3	112
43	Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. *Chest*, **2004**, 126, 420-7	5.3	187
42	Embolie pulmonaire : histoire naturelle, diagnostic, traitement. *Encyclopédie Médico-chirurgicale Pneumologie*, **2004**, 1, 1-8		1
41	Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. *Chest*, **2004**, 126, 35S-62S	5.3	382
40	Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. *Chest*, **2003**, 124, 247-54	5.3	221
39	Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension. *American Journal of Respiratory and Critical Care Medicine*, **2003**, 167, 1433-9	10.2	247
38	The CX3C chemokine fractalkine in allergic asthma and rhinitis. *Journal of Allergy and Clinical Immunology*, **2003**, 112, 1139-46	11.5	73
37	Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension. *Journal of the American College of Cardiology*, **2003**, 41, 1380-6	15.1	274
36	Primary pulmonary hypertension: Current therapy. *Progress in Cardiovascular Diseases*, **2002**, 45, 115-28	8.5	48
35	Inhaled iloprost for severe pulmonary hypertension. *New England Journal of Medicine*, **2002**, 347, 322-9	59.2	1308
34	Pulmonary artery pressure-flow relations after prostacyclin in primary pulmonary hypertension. *American Journal of Respiratory and Critical Care Medicine*, **2002**, 165, 338-40	10.2	78
33	Chemokine RANTES in severe pulmonary arterial hypertension. *American Journal of Respiratory and Critical Care Medicine*, **2002**, 165, 534-9	10.2	202
32	New treatments for pulmonary arterial hypertension. *American Journal of Respiratory and Critical Care Medicine*, **2002**, 165, 1209-16	10.2	101
31	CX(3)C chemokine fractalkine in pulmonary arterial hypertension. *American Journal of Respiratory and Critical Care Medicine*, **2002**, 165, 1419-25	10.2	216
30	Pulse wave reflection in pulmonary hypertension. *Journal of the American College of Cardiology*, **2002**, 39, 743-4	15.1	7
29	Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. *Journal of the American College of Cardiology*, **2002**, 39, 1496-502	15.1	478
28	Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. *Journal of the American College of Cardiology*, **2002**, 40, 780-8	15.1	1074
27	Bosentan therapy for pulmonary arterial hypertension. *New England Journal of Medicine*, **2002**, 346, 896-903	59.2	2098

26	Diagnostic strategy for patients with suspected pulmonary embolism: a prospective multicentre outcome study. *Lancet, The*, **2002**, 360, 1914-20	40	330
25	Complete results of the first randomized, placebo-controlled study of bosentan, a dual endothelin receptor antagonist, in pulmonary arterial hypertension. *Current Therapeutic Research*, **2002**, 63, 227-246	2.4	21
24	Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. *American Journal of Respiratory and Critical Care Medicine*, **2002**, 165, 800-4	10.2	1041
23	Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. *New England Journal of Medicine*, **2001**, 345, 325-34	59.2	579
22	Pulmonary artery pulse pressure and wave reflection in chronic pulmonary thromboembolism and primary pulmonary hypertension. *Journal of the American College of Cardiology*, **2001**, 37, 1085-92	15.1	133
21	Risk factors for pulmonary arterial hypertension. *Clinics in Chest Medicine*, **2001**, 22, 459-75	5.3	94
20	Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. *Lancet, The*, **2001**, 358, 1119-23	40	1175
19	Pathobiology of pulmonary hypertension. The role of platelets and thrombosis. *Clinics in Chest Medicine*, **2001**, 22, 451-8	5.3	132
18	Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. *Journal of Clinical Investigation*, **2001**, 108, 1141-1150	15.9	391
17	Systematic lung scans reveal a high frequency of silent pulmonary embolism in patients with proximal deep venous thrombosis. *Archives of Internal Medicine*, **2000**, 160, 159-64		145
16	High prevalence of detectable deep venous thrombosis in patients with acute pulmonary embolism. *Chest*, **1999**, 116, 903-8	5.3	133
15	Angioscopic video-assisted pulmonary endarterectomy for post-embolic pulmonary hypertension. *European Journal of Cardio-thoracic Surgery*, **1999**, 16, 38-43	3	52
14	Treatments for severe pulmonary hypertension. *Lancet, The*, **1999**, 353, 338-40	40	16
13	A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prˆvention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group. *New England Journal of Medicine*, **1998**, 338, 409-15	59.2	1406
12	Pulmonary edema complicating continuous intravenous prostacyclin in pulmonary capillary hemangiomatosis. *American Journal of Respiratory and Critical Care Medicine*, **1998**, 157, 1681-5	10.2	129
11	Nitric oxide deficiency in fenfluramine- and dexfenfluramine-induced pulmonary hypertension. *American Journal of Respiratory and Critical Care Medicine*, **1998**, 158, 1061-7	10.2	85
10	Chemokine macrophage inflammatory protein-1alpha mRNA expression in lung biopsy specimens of primary pulmonary hypertension. *Chest*, **1998**, 114, 50S-51S	5.3	56
9	Primary pulmonary hypertension associated with the use of fenfluramine derivatives. *Chest*, **1998**, 114, 195S-199S	5.3	77

8	A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire. *New England Journal of Medicine*, **1997**, 337, 663-9	59.2	630
7	Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. *New England Journal of Medicine*, **1996**, 334, 682-7	59.2	941
6	Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. *New England Journal of Medicine*, **1996**, 335, 609-16	59.2	962
5	Increased plasma serotonin in primary pulmonary hypertension. *American Journal of Medicine*, **1995** , 99, 249-54	2.4	445
4	Surgical management of unresolved pulmonary embolism. A personal series of 72 patients. *Chest*, **1995**, 107, 52S-55S	5.3	44
3	Primary pulmonary hypertension in a patient with a familial platelet storage pool disease: role of serotonin. *American Journal of Medicine*, **1990**, 89, 117-20	2.4	139
2	Cardiopulmonary effects of a single oral dose of almitrine at rest and on exercise in patients with hypoxic chronic airflow obstruction. *Chest*, **1986**, 89, 174-9	5.3	29
1	Inhibition of hypoxic pulmonary vasoconstriction by nifedipine. *New England Journal of Medicine*, **1981**, 304, 1582-5	59.2	223